New Recruiting Trial: Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy
WHY IT MATTERS
This trial offers metastatic renal cell carcinoma patients who achieved complete or major response to immunotherapy a chance to participate in research that could determine whether surgical removal of the primary kidney improves long-term outcomes.
Researchers are looking for kidney cancer patients whose tumors shrank significantly or disappeared after immunotherapy treatment. This new trial will study whether removing the original kidney after successful immunotherapy helps prevent the cancer from coming back. The study starts in May 2026 and is currently accepting patients.
NCT ID: NCT06882486 Title: Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy Status: RECRUITING Phase: NA Sponsor: Institut Paoli-Calmettes Start date: 2026-05-01 URL: https://clinicaltrials.gov/study/NCT06882486 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If you have metastatic kidney cancer that responded well to immunotherapy, ask your oncologist immediately whether you meet eligibility criteria for NCT06882486, as enrollment is now open.